Yes, I didn't know this about MSB.
That they are seeing positive results in stage 3 trials shows that these specific MSC's can be made to improve the condition, and has implications for Cynata's product. Whether in general, MSC's such as CYP-001 can do the same needs to be confirmed by our own clinical trials.
I think that the response to CYP-001 in subjects in our GvHD trial will be viewed more in the context of other applications of Cymerus than in GvHD treatments per se.
Yes, I didn't know this about MSB. That they are seeing positive...
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $44.90M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.5¢ | 25.0¢ | $5.869K | 22.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29342 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 15.47pm 11/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |